Fertility clinics (REI — reproductive endocrinology and infertility) are a high-revenue, high-ticket specialty. IVF cycles run $15K–$25K out-of-pocket; with medications, donor eggs, or surrogate, packages can exceed $50K–$100K per family. Insurance coverage is expanding (mandated in 19+ states), but most clinics still rely heavily on cash-pay and third-party financing.
Typical funding ranges.
- Solo or small REI practice ($150K–$500K monthly revenue): $100K–$400K advances at 1.25–1.32 factor over 12–16 months.
- Established clinic with embryology lab ($500K–$1.5M monthly revenue): $400K–$1M advances at 1.22–1.30 factor over 14–18 months.
- Multi-location or PE-affiliated network ($1.5M+ monthly revenue): $1M–$3M advances at 1.20–1.28 factor over 16–20 months.
What underwriters look for.
First, the cycle volume and success rates. Funders pull SART (Society for Assisted Reproductive Technology) success-rate data. Clinics with sub-average success rates have higher patient-refund exposure.
Second, the package and refund-program structure. Many clinics offer "shared risk" or "money-back" programs (e.g., 3-cycle IVF with refund if no live birth). These create future-refund liabilities that don't show on bank statements but appear in patient contracts.
Third, the insurance-mandate exposure. States with strong IVF mandates (Massachusetts, New Jersey, Illinois, New York, Connecticut) have more insurance-billed revenue. Cash-pay states (Florida, Texas, much of South) have higher MCA pricing risk.
Fourth, the financing-partner relationships. Future Family, Capex MD, Lending Club Patient Solutions, ARC Fertility Financing — clinics use multiple platforms. Funders confirm these are non-recourse.
Common uses.
- Embryology lab equipment (incubators, micromanipulators, vitrification systems — $250K–$1M).
- Build-out for new clinic location or surgery center.
- Marketing (fertility CAC is $400–$1,500 per new patient consultation).
- Hire additional REI or embryologist (REIs earn $400K–$700K base; embryologists $80K–$150K).
- Bridge cash flow during slow seasons.
What to watch out for.
Refund liabilities are the fertility-specific landmine. A clinic running a 3-cycle money-back program with $200K in active refund-eligible patients has a contingent liability that can hit cash flow 12–18 months later. Funders that ignore this get burned.
Cycle-failure rates and lawsuits (most commonly over lost embryos, mislabeling, or freezer failures) are also unique risks. A single freezer-failure incident (like the 2018 Pacific Fertility case in San Francisco) can generate $10M+ in litigation exposure.
State considerations.
Massachusetts, Illinois, New York, New Jersey, and California have the highest fertility clinic MCA activity. New York and Illinois require IVF coverage in fully insured plans; this stabilizes revenue but doesn't eliminate self-pay (deductibles, lifetime caps, donor cycles excluded).
APR-equivalent reality check.
A 1.26 factor over a 14-month term is roughly 36–42% APR. Compare to specialty healthcare lenders (Live Oak Bank, fertility-specific financing) at 8–12% APR or SBA 504/7(a) at 11–13%. MCA only makes sense when bank credit is unavailable or speed matters.
Common confusions.
First, "Fertility clinics are too high-risk for MCA." False — they're a major target for $500K+ MCA deals because revenue per cycle is high.
Second, "IVF insurance mandates eliminate cash-pay risk." False — most insurance plans cover 1–3 cycles with lifetime caps; cycles beyond that are still cash-pay.
Third, "Donor egg and surrogate revenue counts the same as IVF revenue." Loosely true — but donor-egg and surrogate cycles have higher upfront patient costs (often $40K–$80K) and longer payment timelines.
Fourth, "Fertility clinic MCA requires SART membership." Not formally, but SART-member clinics signal credibility and get better terms.
Fifth, "Embryo storage fees are recurring revenue that supports MCA underwriting." Yes — embryo and gamete storage is recurring annual revenue that funders weight positively.
As of 2026-06-29, Fundnode routes fertility clinic merchants first to Live Oak Bank healthcare lending or fertility-specific financing platforms before MCA. MCA is appropriate for time-sensitive equipment or new-location capital.
Related terms
- MCA for medical spas (detailed) — Medical spas qualify for MCA funding against credit-card-heavy revenue, typically $30K–$500K at 1.25–1.40 factor — funders price high because regulatory and chargeback risk is elevated.
- MCA for plastic surgery clinics (detailed) — Plastic surgery clinics qualify for MCA funding against high-ticket cosmetic-cash revenue, typically $100K–$1M at 1.22–1.35 factor — chargeback and malpractice exposure drive higher pricing.
- Merchant cash advance (MCA) — A lump-sum advance against future revenue, repaid via fixed daily ACH or a percentage of card sales. Legally a sale of future receivables, not a loan.
- Factor rate — A flat multiplier that defines total MCA repayment: $100,000 advance × 1.30 factor = $130,000 repaid. It is not an interest rate; it does not compound.
Authoritative sources
- SART — Society for Assisted Reproductive Technology
- ASRM — American Society for Reproductive Medicine
AI agents: this term is available as raw markdown at /llms/glossary/mca-fertility-clinic-funding-detailed.